Traders should monitor upcoming regulatory filings in Germany and the EU, as well as initiation of patient enrollment in Q2 2026. Positive trial initiation could drive speculative upside in this micro-cap biotech, though dilution risk remains high given typical capital needs for clinical trials.
Price Chart
Executive Summary
Silexion Therapeutics received formal approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for its RNAi therapy SIL204 in locally advanced pancreatic cancer, marking its transition to a clinical-stage company. The decision follows positive preclinical results and toxicology study completion, with trials expected to start in Q2 2026.
Key Facts
- Received Israeli Ministry of Health approval to initiate Phase 2/3 trial for SIL204 in pancreatic cancer
- Positive preclinical results showed significant anti-tumor activity in multiple models
- Toxicology studies completed successfully
- Trial initiation expected in Q2 2026
- Plans to file for Phase 2/3 trial in Germany by end of Q1 2026, EU-wide filings in early 2027
- SIL204 targets broad range of KRAS mutations present in >90% of pancreatic cancers
Financial Impact
Potential long-term value creation through clinical development of SIL204; no immediate revenue impact
Risk Factors
- High risk of clinical trial failure, especially in oncology development
- Need for significant additional capital, likely leading to future dilution
- Regulatory delays in Germany or EU despite Israeli approval
- Small market cap ($4M) increases volatility and susceptibility to sentiment shifts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261245 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1746 (−13.52%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1746 (+33.56%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1746 (−36.97%) |
Sep 30, 2026 26d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1746 (+37.04%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1746 (+45.09%) |
Sep 29, 2026 27d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1746 (+45.16%) |
Sep 28, 2026 28d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1746 (−29.71%) |
Sep 28, 2026 28d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1746 (−29.71%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1746 (+29.71%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1746 (+58.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers